MEDIAN Technologies coauthors a poster to be presented at the 2011 ASCO Annual Meeting (June, 3-7, Chicago)
MEDIAN Technologies (ALMDT), the leading provider of clinical applications for quantitative management of treatment response in oncology imaging, today announced that it is a coauthor on a poster to be presented at the 2011 Annual Congress of the American Society of Clinical Oncology (ASCO), to be held June 3-7 at the McCormick Place venue in Chicago, IL.
Together with researchers at the University of Minnesota, MEDIAN Technologies has written a poster entitled “Computer-aided volumetry analysis in assessing pulmonary chemotherapy response in advanced NSCLC comparing with RECIST criteria”. The poster (#10593) will be presented between 8 am and noon on June 6, during the “Tumor Biology” session in Hall A.
For more information on the poster, visit: http://abstract.asco.org/AbstView_102_83027.html
“The ASCO annual meeting is an event that experts in this field cannot afford to miss and we are particularly pleased that the University of Minnesota researchers will be presenting this poster”, commented MEDIAN Technologies’ Chairman and CEO Fredrik Brag. “This is an especially strategic presentation because the research is a perfect illustration of our CTIS solution for performing clinical trials in oncology, which will be presented at the ASCO meeting for the first time this year”, he added.
The authors are: L. Ding, R. L. Bliss, M. Ingebrand, T. Allen, P. Ives, A. Dudek, R. A. Kratzke; University of Minnesota, Minneapolis, MN; MEDIAN Technologies Inc., Minneapolis, MN; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN.
About Median Technologies.
Median Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. Median Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. Median serves two primary markets: drug development and patient care. Median has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.
Founded in 2002, Median Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. Median has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.
Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup.
“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”